A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report

被引：14

作者：

Humayun F. ^{[1
]}

Shehab T.M. ^{[1
,2
,5
]}

Tworek J.A. ^{[3
]}

Fontana R.J. ^{[4
]}

机构：

[1] Department of Internal Medicine, St. Joseph Mercy Health System, Ypsilanti

[2] Section of Gastroenterology, St. Joseph Mercy Health System, Ypsilanti

[3] Department of Pathology, St. Joseph Mercy Health System, Ypsilanti

[4] Department of Internal Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor

[5] Huron Gastro/Center for Digestive Care, Ypsilanti

来源：

Journal of Medical Case Reports | / 1卷 / 1期

关键词：

Smoking Cessation; Paroxetine; Bupropion; Hepatic Adverse Event; Autoimmune Feature;

D O I：

10.1186/1752-1947-1-88

中图分类号：

学科分类号：

摘要：

Background: Bupropion is approved for the treatment of mood disorders and as an adjuvant medication for smoking cessation. Bupropion is generally well tolerated and considered safe. Two randomized controlled trials of bupropion therapy for smoking cessation did not report any hepatic adverse events. However, there are three reports of severe but non-fatal bupropion hepatotoxicity published in the literature. Case Presentation: We present the case of a 55-year old man who presented with jaundice and severe hepatic injury approximately 6 months after starting bupropion for smoking cessation. Laboratory evaluation demonstrated a mixed picture of hepatocellular injury and cholestasis. Liver biopsy demonstrated findings consistent with severe hepatotoxic injury due to drug induced liver injury. Laboratory testing was also notable for positive autoimmune markers. The patient initially had clinical improvement with steroid therapy but eventually died of infectious complications. Conclusion: This report represents the first fatal report of bupropion related hepatotoxicity and the second case of bupropion related liver injury demonstrating autoimmune features. The common use of this medication for multiple indications makes it important for physicians to consider this medication as an etiologic agent in patients with otherwise unexplained hepatocellular jaundice. © 2007 Humayun et al; licensee BioMed Central Ltd.

引用

共 13 条

[1]

Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B., A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation, N Engl J Med, 340, 9, pp. 685-691, (1999)

[2]

Oslin D.W., Duffy K., The rise of serum aminotransferases in a patient treated with bupropion, J Clin Psychopharmacol, 13, 5, pp. 364-365, (1993)

[3]

Hu K.Q., Tiyyagura L., Kanel G., Redeker A.G., Acute hepatitis induced by bupropion, Dig Dis Sci, 45, 9, pp. 1872-1873, (2000)

[4]

Alvaro D., Onetti-Muda A., Moscatelli R., Attili A.F., Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking. A case report, Dig Liver Dis, 33, 8, pp. 703-706, (2001)

[5]

Tucker W.E., Preclinical toxicology of bupropion: An overview, J Clin Psychiatry, 44, 5 PART 2, pp. 60-62, (1983)

[6]

Seeff L.B., Watkins P.W., Drug induced liver injury: Summary of a single topic clinical research conference, Hepatology, 43, pp. 618-631, (2006)

[7]

Abe M., Furukawa S., Takayama S., Michitaka K., Minami H., Yamamoto K., Horiike N., Onji M., Drug-induced hepatitis with autoimmune features during minocycline therapy, Intern Med, 42, 1, pp. 48-52, (2003)

[8]

Maria V.A., Victorino R.M., Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis, Hepatology, 26, 3, pp. 664-669, (1997)

[9]

Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., Chapman R.W., Cooksley W.G.E., Czaja A.J., Desmet V.J., Donaldson P.T., Eddleston A.L.W.F., Fainboim L., Heathcote J., Hombert J.-C., Hoofnagle J.H., Kakumu S., Krawitt E.L., Mackay I.R., MacSween R.N.M., Maddrey W.C., Manns M.P., McFarlane I.G., Meyer zum Buschenfelde K.H., Mieli-Vergani G., Nakanuma Y., Nishioka M., Penner E., Porta G., Portmann B.C., Reed W.D., Rodes J., Schalm S.W., Scheuer P.J., Schrumpf E., Sek

[10]

Bjornsson E., Olsson R., Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 2, pp. 481-489, (2005)

← 1 2 →